HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price shot up 3.9% on Monday . The stock traded as high as $15.37 and last traded at $15.19. 21,383 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 106,304 shares. The stock had previously closed at $14.61.
Analyst Ratings Changes
Separately, StockNews.com raised HUTCHMED from a "hold" rating to a "buy" rating in a report on Friday, March 21st.
View Our Latest Stock Report on HUTCHMED
HUTCHMED Stock Performance
The business's 50 day moving average is $14.91 and its 200-day moving average is $15.62. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Institutional Trading of HUTCHMED
Several institutional investors have recently modified their holdings of the stock. Barclays PLC lifted its stake in HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after buying an additional 2,255 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of HUTCHMED by 49.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after acquiring an additional 899 shares during the last quarter. Blue Trust Inc. lifted its position in shares of HUTCHMED by 99.9% in the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after acquiring an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after acquiring an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC purchased a new stake in shares of HUTCHMED during the fourth quarter worth approximately $230,000. Institutional investors and hedge funds own 8.82% of the company's stock.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
